According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers. Did ...

Discover how personalized medicine uses genetics and data to create tailored treatments, improving outcomes in cancer, rare diseases, and more. Explore its future in healthcare.

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of ...

Collin Morikawa, ranked 5th in the world, is seeking his first PGA Tour victory since October 2023 at the Rocket Classic in ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Vertex Pharmaceuticals has received a “Moderate Buy” consensus from 29 brokerages, with most analysts either holding or ...

Sales of the ground-breaking cystic fibrosis (CF) drug Kaftrio was the main driver behind revenues of a Dublin unit of Vertex Pharmaceuticals surging to $2.63bn (€2.26bn) last year. New accounts show ...

Diabetes affects many people in the world, type 1 diabetes being a condition that can affect anyone, causing them to be on ...

Analysts remain bullish on Vertex Pharmaceuticals as HC Wainwright reaffirmed its buy rating with a $550 price target.

DelveInsight's BAFF- and APRIL-targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast ...

This was the stock's second consecutive day of gains.